AR079941A2 - Organismos clostridium atenuados recombinados y vacuna - Google Patents
Organismos clostridium atenuados recombinados y vacunaInfo
- Publication number
- AR079941A2 AR079941A2 ARP110100176A ARP110100176A AR079941A2 AR 079941 A2 AR079941 A2 AR 079941A2 AR P110100176 A ARP110100176 A AR P110100176A AR P110100176 A ARP110100176 A AR P110100176A AR 079941 A2 AR079941 A2 AR 079941A2
- Authority
- AR
- Argentina
- Prior art keywords
- organisms
- attentioned
- recombined
- vaccine
- attenuated
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000193403 Clostridium Species 0.000 title 1
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 3
- 101710197219 Alpha-toxin Proteins 0.000 abstract 3
- 101710124951 Phospholipase C Proteins 0.000 abstract 3
- 239000002776 alpha toxin Substances 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 241000193468 Clostridium perfringens Species 0.000 abstract 2
- 101100069896 Caenorhabditis elegans his-68 gene Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Feed For Specific Animals (AREA)
Abstract
Organismos Clostridium perfringens atenuados, que expresan una toxina alfa sustancialmente no toxica. La toxina alfa expresada es una muteína de delecion a la que, en relacion con la toxina alfa de la toxina alfa madura de la cepa 13 de Clostridium perfringens, le faltan por lo menos 9 residuos de aminoácidos consecutivos, que incluyen His68. La presente acta revela además organismos atenuados que codifican las muteínas, y también, el uso de dichos organismos atenuados como vacunas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79255306P | 2006-04-17 | 2006-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079941A2 true AR079941A2 (es) | 2012-02-29 |
Family
ID=38625523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101608A AR060471A1 (es) | 2006-04-17 | 2007-04-16 | Organismos clostridium recombinantes atenuados y vacuna |
| ARP110100176A AR079941A2 (es) | 2006-04-17 | 2011-01-19 | Organismos clostridium atenuados recombinados y vacuna |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101608A AR060471A1 (es) | 2006-04-17 | 2007-04-16 | Organismos clostridium recombinantes atenuados y vacuna |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7732187B2 (es) |
| EP (2) | EP2368571A1 (es) |
| JP (2) | JP5551933B2 (es) |
| KR (1) | KR20080110908A (es) |
| CN (1) | CN101489584B (es) |
| AR (2) | AR060471A1 (es) |
| AU (1) | AU2007240949B2 (es) |
| BR (1) | BRPI0711572A2 (es) |
| CA (1) | CA2649426C (es) |
| CO (1) | CO6140037A2 (es) |
| EC (1) | ECSP088827A (es) |
| ES (1) | ES2401810T3 (es) |
| IL (1) | IL194714A (es) |
| MX (1) | MX2008013451A (es) |
| NO (1) | NO20084810L (es) |
| NZ (1) | NZ571970A (es) |
| PE (1) | PE20080167A1 (es) |
| PL (1) | PL2007420T3 (es) |
| RU (2) | RU2445364C2 (es) |
| TW (1) | TWI338045B (es) |
| UA (2) | UA109105C2 (es) |
| WO (1) | WO2007123850A2 (es) |
| ZA (1) | ZA200808872B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| US20060083750A1 (en) * | 1999-11-19 | 2006-04-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| JP2011519049A (ja) * | 2008-04-29 | 2011-06-30 | イミューンエクサイト インコーポレイテッド | 免疫調節組成物およびその使用方法 |
| EP2613802A4 (en) * | 2010-09-10 | 2014-03-26 | Viropharma Inc | ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME |
| GEP201706766B (en) | 2011-07-22 | 2017-10-25 | Los Angeles Biomedical Res Center | Methods and compositions for vaccinating against staphylococcus aureus |
| AR090219A1 (es) * | 2012-03-02 | 2014-10-29 | Regeneron Pharma | Anticuerpos humanos frente a toxinas de clostridium difficile |
| ES2759583T3 (es) | 2012-10-26 | 2020-05-11 | Intervet Int Bv | Vacunas de Salmonella de protección cruzada |
| US10130691B2 (en) | 2013-03-15 | 2018-11-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods for treating fungal and bacterial pathogens |
| EP3426287A4 (en) | 2016-03-09 | 2020-03-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
| CN109602898B (zh) * | 2018-12-28 | 2022-02-22 | 江苏省农业科学院 | 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| GB202019767D0 (en) | 2020-12-15 | 2021-01-27 | Chain Biotechnology Ltd | Compostitions and methods |
| CN114621963A (zh) * | 2022-03-11 | 2022-06-14 | 牧原食品股份有限公司 | 一种猪魏氏梭菌a型的亚单位疫苗及其制备 |
| CN116970505A (zh) * | 2022-04-22 | 2023-10-31 | 金宇保灵生物药品有限公司 | 一种A型产气荚膜梭菌α毒素的产毒培养基及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1483042A (en) * | 1974-07-29 | 1977-08-17 | Lapointe J | Anti-tumour product of bacterial origin |
| SU627611A1 (ru) | 1977-09-30 | 1980-02-05 | В.П. Землякова | Вакцинный препарат в.п. земл ковой против клостридиозов животных и птиц |
| GB9115332D0 (en) * | 1991-07-16 | 1991-08-28 | Connaught Lab | Manipulation of gene copy number in bordetella |
| NZ253189A (en) * | 1992-05-20 | 1996-08-27 | Secr Defence | Peptides comprising amino acid sequences of clostridium perfringens alpha toxins, vaccines containing them, antibodies and their use |
| GB9605222D0 (en) | 1996-03-12 | 1996-05-15 | Secr Defence | Clostridium perfringens epsilon toxin vaccines |
| ES2276448T3 (es) * | 1997-06-20 | 2007-06-16 | Intervet International Bv | Vacuna contra clostridium perfringens. |
| RU2129441C1 (ru) * | 1997-12-10 | 1999-04-27 | Пирожков Михаил Константинович | Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят |
| US6399074B1 (en) * | 1998-07-24 | 2002-06-04 | Megan Health, Inc. | Live attenuated salmonella vaccines to control avian pathogens |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US6908620B2 (en) * | 2002-12-09 | 2005-06-21 | University Of Georgia Research Foundation, Inc. | Coccidial vaccine and methods of making and using same |
| JP2007512006A (ja) * | 2003-11-10 | 2007-05-17 | ザ ユーエービー リサーチ ファウンデーション | 細菌輸送およびｃｎｓ侵襲を低減させるための組成物およびこの組成物を使用する方法 |
| MY149604A (en) | 2005-04-18 | 2013-09-13 | Schering Plough Ltd | C.perfringens alpha toxoid vaccine |
-
2007
- 2007-04-12 BR BRPI0711572-5A patent/BRPI0711572A2/pt not_active IP Right Cessation
- 2007-04-12 UA UAA201106572A patent/UA109105C2/ru unknown
- 2007-04-12 ES ES07755417T patent/ES2401810T3/es active Active
- 2007-04-12 CN CN2007800225963A patent/CN101489584B/zh not_active Expired - Fee Related
- 2007-04-12 WO PCT/US2007/009135 patent/WO2007123850A2/en not_active Ceased
- 2007-04-12 MX MX2008013451A patent/MX2008013451A/es active IP Right Grant
- 2007-04-12 KR KR1020087027923A patent/KR20080110908A/ko not_active Ceased
- 2007-04-12 JP JP2009506518A patent/JP5551933B2/ja not_active Expired - Fee Related
- 2007-04-12 AU AU2007240949A patent/AU2007240949B2/en not_active Ceased
- 2007-04-12 CA CA2649426A patent/CA2649426C/en not_active Expired - Fee Related
- 2007-04-12 RU RU2008144913/10A patent/RU2445364C2/ru active
- 2007-04-12 RU RU2011147308/10A patent/RU2593945C2/ru active
- 2007-04-12 US US11/734,454 patent/US7732187B2/en active Active
- 2007-04-12 PL PL07755417T patent/PL2007420T3/pl unknown
- 2007-04-12 EP EP11157448A patent/EP2368571A1/en not_active Withdrawn
- 2007-04-12 NZ NZ571970A patent/NZ571970A/en not_active IP Right Cessation
- 2007-04-12 EP EP07755417A patent/EP2007420B1/en active Active
- 2007-04-16 AR ARP070101608A patent/AR060471A1/es active IP Right Grant
- 2007-04-16 PE PE2007000464A patent/PE20080167A1/es not_active Application Discontinuation
- 2007-04-17 TW TW096113489A patent/TWI338045B/zh not_active IP Right Cessation
- 2007-12-04 UA UAA200813301A patent/UA95951C2/ru unknown
-
2008
- 2008-10-12 IL IL194714A patent/IL194714A/en not_active IP Right Cessation
- 2008-10-16 EC EC2008008827A patent/ECSP088827A/es unknown
- 2008-10-16 ZA ZA200808872A patent/ZA200808872B/xx unknown
- 2008-10-17 CO CO08110815A patent/CO6140037A2/es unknown
- 2008-11-14 NO NO20084810A patent/NO20084810L/no not_active Application Discontinuation
-
2009
- 2009-12-17 US US12/640,645 patent/US7807456B2/en active Active
-
2010
- 2010-08-27 US US12/869,813 patent/US7972604B2/en active Active
-
2011
- 2011-01-19 AR ARP110100176A patent/AR079941A2/es not_active Application Discontinuation
-
2013
- 2013-09-17 JP JP2013191854A patent/JP2013255518A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079941A2 (es) | Organismos clostridium atenuados recombinados y vacuna | |
| PE20161551A1 (es) | Vacuna de pcsk9 | |
| AR040204A1 (es) | Composicion de vacuna meningococica multivalente | |
| DK1968632T3 (da) | Forbedret influenzavaccine | |
| CL2009001874A1 (es) | Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661. | |
| CL2009000091A1 (es) | Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas. | |
| MX2011006846A (es) | Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv. | |
| WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
| AR074311A1 (es) | Variantes de subtilisina aislada de bacillus, con actividad proteolitica | |
| ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| BRPI0608796B8 (pt) | método para a preparação de um extrato de planta compreendendo bacuquiol | |
| ECSP099079A (es) | Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos | |
| IN2015DN02729A (es) | ||
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| PE20121685A1 (es) | Antigeno ndv recombinante y usos del mismo | |
| CO6150187A2 (es) | Vacunas para malaria | |
| ATE547118T1 (de) | Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung | |
| NZ594268A (en) | Grass peptides for vaccine | |
| NZ602380A (en) | Peptides for vaccine against birch allergy | |
| ES2670799T3 (es) | Inmunógenos desintoxicados de Escherichia coli | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| CL2013002631A1 (es) | Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura. | |
| MX344183B (es) | Proteina antimicrobiana. | |
| BR112014001844A2 (pt) | gene induzindo o alongamento de raízes ou aumentando a biomassa, e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |